- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
R2 lands distribution partner for Japan
Mammography CAD developer R2 Technology of Los Altos, CA, has signed a product distribution deal with Marubeni America that gives Marubeni rights to sell its ImageChecker product in Japan. The deal extends for three years and is subject to minimum
Mammography CAD developer R2 Technology of Los Altos, CA, has signed a product distribution deal with Marubeni America that gives Marubeni rights to sell its ImageChecker product in Japan. The deal extends for three years and is subject to minimum purchase requirements. R2 executives believe that Japan will establish a national mammography screening program within the next two years, creating demand for ImageChecker.
In related news, R2 closed a $6 million round of venture financing last month, with Marubeni America and its parent firm, Marubeni Corp., joining with R2s other financial backers in plowing more cash into the firm. R2 said it would use the money to finance its marketing efforts for ImageChecker in the U.S. and Japan.
© 1999 Miller Freeman, Inc.All rights reserved.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
